GlassScriptPhysician profile
William Crosland
NPI 1518102219
$4,054.89
in general payments reported to CMS, 2019-2025
25 companies · $858 in 2025
The $858 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $239 · 2021: $767 · 2022: $452 · 2023: $251 · 2024: $1,151 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $588.06 | 2020-2025 | Opticross, Avvigo Guidance System |
| Cvrx, INC. | $488.37 | 2024-2025 | Barostim Neo System |
| Inari Medical, INC. | $409.66 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $333.06 | 2021-2025 | |
| Abbott Laboratories | $303.54 | 2021 | |
| Abiomed | $284.27 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $245.03 | 2020-2025 | Lifevest |
| Cardiovascular Systems INC. | $233.59 | 2019-2023 | Diamondback Coronary |
| Shockwave Medical, INC | $221.48 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $171.18 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $117.97 | 2019-2021 | |
| Livanova USA, INC. | $112.13 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $101.06 | 2023-2024 | Inpefa |
| Medtronic, INC. | $67.17 | 2025 | Ffrangio |
| Bayer Healthcare Pharmaceuticals INC. | $64.66 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $62.71 | 2025 | Flowtriever |
| Pfizer INC. | $60.10 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $38.73 | 2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $32.21 | 2021-2022 | |
| Angiodynamics, INC. | $27.78 | 2025 | Alphavac |
| Recor Medical INC | $21.99 | 2024 | Paradise Renal Denervation System |
| Amgen INC. | $20.23 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.65 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.81 | 2025 | Jardiance |
| Terumo Medical Corporation | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Crosland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.